These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 9678787

  • 1. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 2. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D, Oschry Y, Fainaru M, Eisenberg S.
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [Abstract] [Full Text] [Related]

  • 3. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia.
    Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Mikami Y, Mikami Y, Nakamura H.
    Atherosclerosis; 1994 Apr; 106(2):191-201. PubMed ID: 8060379
    [Abstract] [Full Text] [Related]

  • 4. Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins.
    Bhatnagar D, Durrington PN, Mackness MI, Arrol S, Winocour PH, Prais H.
    Atherosclerosis; 1992 Jan; 92(1):49-57. PubMed ID: 1575821
    [Abstract] [Full Text] [Related]

  • 5. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 6. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
    Nakandakare E, Garcia RC, Rocha JC, Sperotto G, Oliveira HC, Quintão EC.
    Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085
    [Abstract] [Full Text] [Related]

  • 7. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ, Lamon-Fava S, Cole T, Sprecher DL, Cilla DD, Balagtas CC, Rowan JP, Black DM.
    Atherosclerosis; 1996 Nov 15; 127(1):113-22. PubMed ID: 9006811
    [Abstract] [Full Text] [Related]

  • 8. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity.
    Kahri J, Vuorinen-Markkola H, Tilly-Kiesi M, Lahdenperä S, Taskinen MR.
    Atherosclerosis; 1993 Aug 15; 102(1):79-89. PubMed ID: 8257455
    [Abstract] [Full Text] [Related]

  • 9. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A, Massari F, Rodríguez Moncalvo JJ, Rubén Zanchetta J, Insua AM.
    Endocr Pract; 2002 Aug 15; 8(2):96-101. PubMed ID: 11942772
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E, De Gennes JL, Malbecq W, Baigts F.
    Clin Cardiol; 1995 Nov 15; 18(11):621-9. PubMed ID: 8590530
    [Abstract] [Full Text] [Related]

  • 11. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
    Zhao SP, Smelt AH, Leuven JA, Vroom TF, van der Laarse A, van 't Hooft FM.
    Am J Med; 1994 Jan 15; 96(1):49-56. PubMed ID: 8304363
    [Abstract] [Full Text] [Related]

  • 12. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
    Winocour PH, Durrington PN, Bhatagnar D, Ishola M, Mackness M, Arrol S, Anderson DC.
    Atherosclerosis; 1992 Mar 15; 93(1-2):83-94. PubMed ID: 1596307
    [Abstract] [Full Text] [Related]

  • 13. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin.
    Lagrost L, Athias A, Lemort N, Richard JL, Desrumaux C, Châtenet-Duchêne L, Courtois M, Farnier M, Jacotot B, Braschi S, Gambert P.
    Atherosclerosis; 1999 Apr 15; 143(2):415-25. PubMed ID: 10217372
    [Abstract] [Full Text] [Related]

  • 14. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L, Szostak WB.
    Eur J Clin Pharmacol; 1991 Apr 15; 40(1):33-41. PubMed ID: 2060543
    [Abstract] [Full Text] [Related]

  • 15. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB, Peters JR.
    Am J Med; 1987 Nov 27; 83(5B):44-9. PubMed ID: 3318453
    [Abstract] [Full Text] [Related]

  • 16. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E, Chapman MJ.
    J Clin Endocrinol Metab; 2003 Aug 27; 88(8):3738-46. PubMed ID: 12915663
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F, Cenarro A, Ferrando J, Puzo J, Garcia-Otín AL, Mozas P, Pocoví M.
    Am Heart J; 1999 Jul 27; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [Abstract] [Full Text] [Related]

  • 18. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
    Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G.
    Diabetes Metab; 2001 Nov 27; 27(5 Pt 1):604-10. PubMed ID: 11694861
    [Abstract] [Full Text] [Related]

  • 19. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients.
    Kahri J, Sane T, van Tol A, Taskinen MR.
    J Intern Med; 1995 Nov 27; 238(5):429-36. PubMed ID: 7595182
    [Abstract] [Full Text] [Related]

  • 20. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF.
    Am J Cardiol; 1995 Feb 15; 75(5):348-53. PubMed ID: 7856526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.